CA2697990A1 - Medication combinations for the treatment of alcoholism and drug addiction - Google Patents

Medication combinations for the treatment of alcoholism and drug addiction Download PDF

Info

Publication number
CA2697990A1
CA2697990A1 CA2697990A CA2697990A CA2697990A1 CA 2697990 A1 CA2697990 A1 CA 2697990A1 CA 2697990 A CA2697990 A CA 2697990A CA 2697990 A CA2697990 A CA 2697990A CA 2697990 A1 CA2697990 A1 CA 2697990A1
Authority
CA
Canada
Prior art keywords
administered
antagonists
compounds
alcohol
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2697990A
Other languages
English (en)
French (fr)
Inventor
Bankole A. Johnson
Nassima Ait-Daoud Tiouririne
Wendy J. Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2697990A1 publication Critical patent/CA2697990A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2697990A 2007-08-27 2008-05-20 Medication combinations for the treatment of alcoholism and drug addiction Abandoned CA2697990A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96626507P 2007-08-27 2007-08-27
US60/966,265 2007-08-27
PCT/US2008/064232 WO2009029308A1 (en) 2007-08-27 2008-05-20 Medication combinations for the treatment of alcoholism and drug addiction

Publications (1)

Publication Number Publication Date
CA2697990A1 true CA2697990A1 (en) 2009-03-05

Family

ID=40387675

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2697990A Abandoned CA2697990A1 (en) 2007-08-27 2008-05-20 Medication combinations for the treatment of alcoholism and drug addiction

Country Status (4)

Country Link
US (1) US20110065628A1 (enExample)
JP (1) JP2010537990A (enExample)
CA (1) CA2697990A1 (enExample)
WO (1) WO2009029308A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2436573C2 (ru) * 2009-07-27 2011-12-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт психического здоровья Сибирского отделения Российской академии медицинских наук (НИИПЗ СО РАМН) Способ реабилитации больных алкоголизмом

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001032148A1 (en) 1999-10-29 2001-05-10 Euro-Celtique, S.A. Controlled release hydrocodone formulations
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
EP2556830A1 (en) * 2006-12-19 2013-02-13 University Of Virginia Patent Foundation Combined effects of topiramate, ondansetron and naltrexone on alcohol consumption
WO2008095086A2 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
BRPI0908425B8 (pt) 2008-02-28 2021-05-25 Univ Of Virgina Patent Foundation métodos para predizer uma predisposição para desenvolver alcoolismo, e para predizer uma resposta para o tratamento contra alcoolismo, e, uso de um antagonista do receptor de serotonina 5-ht3
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP3064217B1 (en) 2009-01-06 2018-04-18 Galenagen, LLC Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections
GB2480773B (en) 2009-01-06 2013-12-11 Curelon Llc Compositions for the treatment of diarrhea caused by virulent E. coli infections
US20100196436A1 (en) * 2009-01-30 2010-08-05 Gooberman Lance L Implants containing disulfiram and an anti-inflammatory agent
US8791093B2 (en) * 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
RU2402352C1 (ru) * 2009-08-13 2010-10-27 Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) Способ угнетения алкогольной мотивации
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
WO2012003462A1 (en) 2010-07-02 2012-01-05 Johnson Bankole A Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
EP3305317B1 (en) 2011-04-21 2020-06-24 Curemark, LLC Compounds for the treatment of neuropsychiatric disorders
WO2013036721A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
RU2495679C1 (ru) * 2012-07-16 2013-10-20 Станислав Анатольевич Кедик Имплант на основе дисульфирама для лечения пациентов, зависимых от алкоголя или опиатов
US10322120B2 (en) 2012-07-31 2019-06-18 Persion Pharmaceuticals Llc Treating pain in patients with hepatic impairment
US20140161879A1 (en) * 2012-07-31 2014-06-12 Zogenix, Inc. Treating pain in patients with hepatic impairment
WO2014120936A2 (en) * 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
ES2926494T3 (es) 2015-03-26 2022-10-26 Sen Jam Pharmaceutical Llc Combinación de naproxeno y fexofenadina para inhibir los síntomas asociados con veisalgia
US20160279124A1 (en) * 2015-03-27 2016-09-29 Dan Markel Method for Treating Addiction
CA3028731A1 (en) * 2016-06-24 2017-12-28 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of alcohol use disorder
RU2629529C1 (ru) * 2016-08-09 2017-08-29 Ольга Ивановна Салмина-Хвостова Способ лечения алкоголизма
RU2629530C1 (ru) * 2016-08-12 2017-08-29 Ольга Ивановна Салмина-Хвостова Способ лечения алкогольной зависимости
AU2017360910B2 (en) 2016-11-18 2023-11-23 Aegis Therapeutics, Llc Compositions and methods for the treatment of opioid overdose
WO2018191233A1 (en) * 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
CA3071959A1 (en) * 2017-08-22 2019-02-28 Euphoria Beer Development Ltd Enriched alcoholic beverages
WO2019058172A1 (en) 2017-09-07 2019-03-28 Nls-1 Pharma Ag MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES
US11160843B2 (en) * 2018-04-30 2021-11-02 Yale University Oxytocin and opioid antagonists for treatment of social dysfunction disorder
EP3897579A4 (en) * 2018-12-20 2022-11-16 Aegis Therapeutics, LLC COMPOSITIONS, DEVICES AND METHODS FOR TREATING OVERDOSE AND REWARD-RELATED DISORDERS
RU2721606C1 (ru) * 2019-11-08 2020-05-21 Общество с ограниченной ответственностью "Ай Кью Витаминная студия" Фармацевтическая композиция для парентерального капельного введения
WO2021154631A1 (en) 2020-01-30 2021-08-05 Javed Mohammad Combination drug therapies for cns disorders
US20220389509A1 (en) * 2021-05-25 2022-12-08 Raymond F. Anton Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder
US12290596B2 (en) 2021-08-04 2025-05-06 Indivior Uk Limited Compositions and methods for the treatment of opioid overdose
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
WO2025112048A1 (zh) * 2023-12-01 2025-06-05 深圳善康医药科技股份有限公司 用于防止大麻复吸的药物组合物和其应用
WO2025207125A1 (en) * 2024-03-26 2025-10-02 The Regents Of The University Of California Combination pharmacological interventions for obstructive sleep apnea

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US20040167164A1 (en) * 1998-05-05 2004-08-26 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
EP1158973B1 (en) * 1999-02-24 2005-05-04 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
US6740038B2 (en) * 2000-09-29 2004-05-25 New Health Sciences, Inc. Systems and methods for assessing vascular effects of a treatment
US7122308B2 (en) * 2001-02-16 2006-10-17 Centre For Addiction And Mental Health Detection of antidepressant induced mania
US7033771B2 (en) * 2001-05-08 2006-04-25 Takeda Pharmaceutical Company Limited Use of insulin response modulators in the treatment of diabetes and insulin resistance
US20030153590A1 (en) * 2001-08-14 2003-08-14 Oy Contral Pharma Ltd Method of treating alcoholism or alcohol abuse
EP1434875A4 (en) * 2001-08-21 2004-12-22 Smithkline Beecham Corp GENE POLYMORPHISMS AND TREATMENT RESPONSE
WO2003037313A2 (en) * 2001-10-31 2003-05-08 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
ES2639579T3 (es) * 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7163969B2 (en) * 2003-10-14 2007-01-16 Stockhausen, Inc. Superabsorbent polymer aqueous paste and coating
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
DK1928438T3 (da) * 2005-09-26 2013-04-22 Avigen Inc Anvendelse af ibudilast til behandling af stofafhængighed
US20070292880A1 (en) * 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
EP2556830A1 (en) * 2006-12-19 2013-02-13 University Of Virginia Patent Foundation Combined effects of topiramate, ondansetron and naltrexone on alcohol consumption
WO2008095086A2 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
US7844609B2 (en) * 2007-03-16 2010-11-30 Expanse Networks, Inc. Attribute combination discovery
WO2009026381A2 (en) * 2007-08-21 2009-02-26 University Of Virginia Patent Foundation Method, computer program product and system for individual assessment of alcohol sensitivity
BRPI0908425B8 (pt) * 2008-02-28 2021-05-25 Univ Of Virgina Patent Foundation métodos para predizer uma predisposição para desenvolver alcoolismo, e para predizer uma resposta para o tratamento contra alcoolismo, e, uso de um antagonista do receptor de serotonina 5-ht3
WO2009134944A2 (en) * 2008-04-29 2009-11-05 Nodality, Inc. Methods of determining the health status of an individual
US20120115149A1 (en) * 2009-05-01 2012-05-10 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2436573C2 (ru) * 2009-07-27 2011-12-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт психического здоровья Сибирского отделения Российской академии медицинских наук (НИИПЗ СО РАМН) Способ реабилитации больных алкоголизмом

Also Published As

Publication number Publication date
JP2010537990A (ja) 2010-12-09
US20110065628A1 (en) 2011-03-17
WO2009029308A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
US12221654B2 (en) Serotonin transporter gene and treatment of opioid-related disorders
US20110065628A1 (en) Medication Combinations for the Treatment of Alcoholism and Drug Addiction
US20100076006A1 (en) Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
US20100041689A1 (en) Combined Effects of Topiramate and Ondansetron on Alcohol Consumption
US20090318520A1 (en) Use of isoindoles for the treatment of neurobehavioral disorders
US20120115149A1 (en) Serotonin transporter gene and treatment of alcoholism
CN101663028A (zh) 托吡酯和昂丹司琼对酒精消费的联合效果
HK1151091B (en) Serotonin transporter gene and treatment of alcoholism

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140521